Liraglutide — NZ Medication Guide
📋 Reviewed by a Registered Pharmacist NZ — This information is for general educational purposes only and does not replace professional medical advice. Always consult your doctor or pharmacist before starting, stopping, or changing any medication.
What is Liraglutide?
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes and obesity management. This medication is funded by Pharmac under Special Authority for type 2 diabetes with CVD; Saxenda® not funded for obesity.
What is Liraglutide Used For?
Liraglutide (Victoza®) is used for type 2 diabetes to improve glycaemic control, reduce cardiovascular risk, and promote modest weight loss. At a higher dose (Saxenda® 3 mg/day), it is also approved for chronic weight management in adults with obesity.
How Does Liraglutide Work?
Liraglutide is an analogue of GLP-1, a gut hormone that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central hypothalamic receptors. This lowers post-meal glucose, promotes satiety, and reduces caloric intake.
How to Take Liraglutide
Self-administered by subcutaneous injection once daily (any time of day, with or without food). For Victoza®: start at 0.6 mg/day for 1 week, increase to 1.2 mg/day, then 1.8 mg/day. For Saxenda® (weight management): titrate from 0.6 mg/day up to 3 mg/day over 5 weeks.
Common Side Effects of Liraglutide
- Nausea and vomiting (very common — usually improves over 4–8 weeks)
- Diarrhoea or constipation
- Injection site reactions (redness, bruising, nodules)
- Headache
- Reduced appetite
Serious Side Effects — Seek Medical Attention
Contact your doctor or call 111 immediately if you experience any of the following:
- Pancreatitis (rare — stop and seek medical care if persistent severe abdominal pain)
- Thyroid tumours (C-cell tumours seen in rodents — avoid in patients with personal or family history of medullary thyroid carcinoma or MEN2)
- Diabetic retinopathy worsening (with rapid glucose reduction)
- Severe dehydration (from vomiting/diarrhoea)
- Renal impairment (secondary to dehydration)
Drug Interactions
Liraglutide may interact with other medicines. Always inform your doctor and pharmacist of all medications you are taking. Key interactions include:
- Insulin and sulfonylureas (hypoglycaemia risk — consider dose reduction)
- Oral medicines with narrow therapeutic windows (liraglutide slows gastric emptying — affects absorption timing)
- Warfarin (monitor INR)
New Zealand Prescribing Information
Liraglutide (Victoza® 6 mg/mL pre-filled pen) is funded by Pharmac under Special Authority for type 2 diabetes with established cardiovascular disease, as add-on to metformin. Saxenda® (higher-dose liraglutide 3 mg) for weight management is not funded in NZ and requires private purchase. Cardiovascular outcome data from the LEADER trial support liraglutide’s use in high-risk diabetic patients.
Frequently Asked Questions
How do I manage nausea on liraglutide?
Start with the lowest dose (0.6 mg) and increase slowly over weeks. Eat smaller, lower-fat meals. Nausea typically improves significantly within 4–8 weeks. If vomiting is severe, contact your doctor.
Is liraglutide just for diabetes?
At the standard dose (up to 1.8 mg/day), liraglutide is used for type 2 diabetes. At the higher dose of 3 mg/day (Saxenda®), it is approved for weight management in people with obesity. In NZ, Saxenda® is not funded and requires private prescription.
⚠️ Disclaimer: This page is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or a qualified health provider. In New Zealand, medication availability and funding may vary — check with Pharmac or your pharmacist for current information.
Reviewed by a Registered Pharmacist NZ
References & Further Information
The following New Zealand and international resources were used to inform this page: